KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Exact Sciences (EXAS) over the last 17 years, with Q4 2025 value amounting to $956.0 million.

  • Exact Sciences' Cash & Equivalents rose 5909.69% to $956.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $956.0 million, marking a year-over-year increase of 5909.69%. This contributed to the annual value of $956.0 million for FY2025, which is 5909.69% up from last year.
  • Exact Sciences' Cash & Equivalents amounted to $956.0 million in Q4 2025, which was up 5909.69% from $789.0 million recorded in Q3 2025.
  • In the past 5 years, Exact Sciences' Cash & Equivalents registered a high of $1.1 billion during Q1 2021, and its lowest value of $189.8 million during Q1 2022.
  • In the last 5 years, Exact Sciences' Cash & Equivalents had a median value of $475.8 million in 2023 and averaged $499.0 million.
  • As far as peak fluctuations go, Exact Sciences' Cash & Equivalents plummeted by 8280.73% in 2022, and later soared by 18317.88% in 2023.
  • Exact Sciences' Cash & Equivalents (Quarter) stood at $315.5 million in 2021, then decreased by 23.13% to $242.5 million in 2022, then skyrocketed by 149.65% to $605.4 million in 2023, then fell by 0.74% to $600.9 million in 2024, then soared by 59.1% to $956.0 million in 2025.
  • Its Cash & Equivalents stands at $956.0 million for Q4 2025, versus $789.0 million for Q3 2025 and $657.1 million for Q2 2025.